In sensitive breast cancer cell models, Trastuzumab and Lapatinib blocked extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT that in turn inhibited MYC activation and upregulated miR-16, a novel tumor suppressor [34]. The gene discussed is MYC; the disease is neoplasm.